GLOBAL FUND STAKEHOLDERS briefing - PowerPoint PPT Presentation

1 / 19
About This Presentation
Title:

GLOBAL FUND STAKEHOLDERS briefing

Description:

GLOBAL FUND STAKEHOLDERS briefing – PowerPoint PPT presentation

Number of Views:48
Avg rating:3.0/5.0
Slides: 20
Provided by: rya13
Category:

less

Transcript and Presenter's Notes

Title: GLOBAL FUND STAKEHOLDERS briefing


1
  • GLOBAL FUND STAKEHOLDERS briefing
  • 05.FEB.2009

Robert Matiru Manager, GDF
2
Outline
  • Update stakeholders on GDF activities
  • Update on GDF QA Process c.f. GF
  • Update on potential GDF linkage with VPP

3
GDF SERVICES
4
GDF Operational update
  • New multi-year Agreement to be signed with USAID
    for US 15M p.a. making USAID main GDF donor for
    first-line Grants
  • CIDA, Netherlands and Norway continue to be
    donors
  • US 71M for MDR-TB drugs from UNITAID over 5
    years
  • US 11M from UNITAID for Paediatric Grants over 4
    years
  • GDF to supply new Diagnostic Tools funded by
    UNITAID in partnership with FIND and GLI over 3
    years
  • External evaluation of STB Partnership/GDF gives
    GDF strong vote of confidence confirmation of
    mandate for 2008 2012
  • GDF retains ISO 90012000 certification new
    quality manager hired
  • GDF signs MoU with Global Fund

5
Technical Support and ME missions
GDF Missions by Region and Year 2001 -
2007 Key WPRO Western
Pacific, SEARO South-East Asia, EURO Europe,
EMRO Eastern Mediterranean (Middle East), AMRO
the Americas and AFRO Africa.
6
  • Restating the fundamentals

7
Procurement Supply Management (PSM)
Selection
Management
Procurement
Use
Support
Distribution
8
1.1 Product Selection Standardized list of
products in blisters, patient kits and bulk
following WHO guidelines and regimens
Products RHZE (4FDC) RHE (3FDC)
Units Loose 1000 tabs Blisters 672 tabs Loose
1000 tabs Blisters 672 tabs Loose 1000 tabs
Blisters 672 tabs Loose 1000 tabs Blisters 672
tabs Loose 1000 tabs Blisters 672 tabs 50 Vials
RH150/75
RH150/150
EH400/150
E400, Z400, H300
S1g
Cat. I III Patient Kit
Cat. II Patient Kit
9
1.2 Product Selection Paediatric TB drugs
Products RHZ (3FDC)
Units Loose 1000 tabs Strips Loose 1000 tabs
Strips Loose 1000 tabs Strips Loose 1000 tabs
Strips 50 Vials
RH60/30
RH60/60
E100, H100, Z150
S1g
10
1.3 Product Selection Second line drugs
11
1.4 Product Selection
Diagnostic Kits
Equipment starter kit
Consumables kit
12
2. Forecasting Procedures
  • Client completes and Order Form/Technical
    agreement
  • Client works with GDF to finalize patient
    numbers required quantities using Standardized
    GDF quantification tool drugs diagnostics
  • GDF supports client with technical and drug
    management support via annual monitoring mission

13
3.1 Procurement
  • GDF competitively transparently contracts its
    procurement agent
  • The Procurement Agent contracts manufacturers
    through Limited International Competitive Bidding
  • GDF Quality Assurance Process fully compliant
    with Global Fund requirements
  • Bulk procurement, standardization and prompt
    payment policy secure low prices

14
3.2 Procurement
  • Batches under preshipment inspection and quality
    control via independent agent
  • GDF adheres to Interagency Operational Principles
    for Good Pharmaceutical Procurement
  • e-tracking system for country orders
  • All anti TB products supplied by GDF are
    registered by National Regulatory Authority of
    the recipient country where required

15
Key Topics
  • Quality Assurance policy update
  • Global Fund VPP value of formal linkage with GDF

16
GDF Quality Assurance Policy
  • Effective July 2009, all anti-TB Drugs supplied
    by GDF required to be in compliance with the new
    GDF Quality Assurance Policy
  • Option A WHO Prequalification (PQ)
  • Option B Stringent National Drug Regulatory
    Authority approval
  • Option C Interim Assessment Approval Process
  • Note
  • Products shall be found acceptable to the GDF
    where they are (i) manufactured at a site meeting
    the standards defined in options A or B and (ii)
    approved through an Expert Review Committee in an
    Interim Assessment Approval Process which
    assesses products based on the information
    provided in a Pharmaceutical Product
    Questionnaire (PPQ) under the condition that the
    product approval process described under either
    options A or B (ii) is pending.

17
GDF and VPP
  • GDF in discussion with GF about formal linkage to
    VPP
  • Including TB drugs under the VPP via GDF would be
    in keeping with the spirit of practical
    collaboration envisaged by Stop TB
    Partnership-Global Fund MoU
  • Would offer PRs a full service package via one
    mechanism
  • Would facilitate improved consolidation of demand
    and forecasting for suppliers (as per next slide)
  • Would support harmonized reporting on pricing and
    adherence to GF/GDF QA policies
  • Collaboration already underway
  • GF to be involved in GDF procurement agent
    selection processes
  • GDF and GF will harmonize quality control
    procedures using same service provider from Q2
    2009

18
(No Transcript)
19
Thank you
Write a Comment
User Comments (0)
About PowerShow.com